Artemis Hospitals
| インド | トルコ | オーストリア | |
| 骨髄移植術 | から $15,000 | から $36,000 | から $140,000 |
| 非血縁者間同種骨髄移植術 | から $28,000 | から $80,000 | から $180,000 |
| 自家骨髄移植術 | から $11,000 | から $31,500 | から $50,000 |
| 大腸癌に対する放射線療法 | から $3,200 | から $7,000 | から $12,000 |
| 同種骨髄移植術 | から $20,500 | から $65,000 | から $150,000 |
Bookimedは濾胞性リンパ腫治療価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。国に到着時にクリニックで治療代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。濾胞性リンパ腫治療で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。濾胞性リンパ腫治療の旅路でお一人になることはありません。
医師は、HCG Manavata Cancer Centre, Nashikで13年以上の経験を持つ非常に経験豊富な血液腫瘍学者であり、白血病、多発性骨髄腫、骨髄移植において専門知識を持っています。 <\/p>
Grant Medical CollegeおよびSir JJ HospitalでMBBSの学位を取得した後、医師はLokmanya Tilak Municipal Medical College, SionおよびMumbaiで病理学のMDを追求しました。 <\/p>
さらに、医師はMedical College, Calcuttaで臨床血液学のDMを取得し、プロフェッショナリズムと勤勉さで賞を受け、熟練した有能な専門家としての評判を強調しています。<\/p>
医師は放射線腫瘍学のMDを取得しており、コンサルタントとして勤務しています。進んだがん治療技術を専門とし、医師はトモセラピー-H、リニアアクセラレーター、ブラキセラピーを含むサービスを提供しています。これらのモダリティは、周囲の健康な組織への損傷を最小限に抑え、治療効果を高めるために正確な放射線治療を提供するために使用されます。<\/p>
Follicular lymphoma is a treatable chronic disease. While advanced stages are often incurable, 35% to 42% of patients achieve functional cures with modern chemoimmunotherapy. Indian centers provide international protocols like monoclonal antibodies and indigenously developed cellular therapies to ensure long-term remissions and high quality of life.
Bookimed Expert Insight: India represents a strategic choice for lymphoma care because of high-volume centers like Manipal Hospitals, which serves 2,000,000 patients annually. Large medical networks like Apollo Hospitals utilize advanced diagnostics such as sentinel lymph node biopsy and PET-CT to tailor maintenance plans. This scale allows for rapid adoption of biosimilar drugs, making maintenance immunotherapy more accessible compared to many Western regions.
Patient Consensus: Patients note that living with the uncertainty of relapse is the hardest psychological challenge. Many emphasize the importance of visiting a large tertiary center to access specialized pathology reviews and long-term surveillance programs.
First-line follicular lymphoma therapies in Indian hospitals typically involve R-CHOP or Bendamustine plus Rituximab (BR). Second-line treatments move toward Lenalidomide with Rituximab or stem cell transplantation. Indian oncology centers use JCI-accredited protocols and advanced PET-CT imaging to guide these chemo-immunotherapy transitions for hematologic malignancies.
Bookimed Expert Insight: Manipal and Global Hospitals serve over 2,000,000 patients annually. This massive volume allows Indian oncologists to distinguish quickly between indolent and aggressive cases. Centers like HCG Manavata combine 40+ consultants with AI-driven tools like IBM Watson to select the most effective drug regimens for complex relapses.
Patient Consensus: Patients note that doctors often choose between R-CHOP and BR based on individual tolerance. Many suggest confirming if follow-up plans include Rituximab maintenance to prevent early recurrence.
CAR T-cell therapy is available in India for relapsed or refractory follicular lymphoma. Indian regulators have approved indigenous products like NexCAR19 and Qartemi. These therapies treat patients who have failed at least two prior treatment lines. The therapy is provided at certified tertiary oncology centers.
Bookimed Expert Insight: Indigenous Indian CAR T-cell manufacturing has created a unique accessibility model. Centers like HCG Manavata Cancer Centre integrate advanced hematology with high patient volumes. While many seek this for aggressive lymphomas, its rollout for follicular cases is expanding within major medical networks like Apollo and Manipal. This infrastructure allows patients to access advanced cell processing at a fraction of international costs.
Patient Consensus: Patients emphasize that this is a late-stage option requiring relocation to a city with a specialized center. Most advice focuses on securing comprehensive biopsy and PET-CT records before the first consultation to avoid delays.
Follicular lymphoma patients in India see a 5-year survival rate of 92% at modern tertiary cancer centers. The 10-year overall survival rate remains high at 85%. These outcomes match global standards due to advanced chemoimmunotherapy protocols and the widespread use of monoclonal antibodies like Rituximab.
Bookimed Expert Insight: High-volume networks like Manipal Hospitals and Apollo Hospitals offer a distinct advantage for chronic management. These institutions manage over 1,000,000 international patients annually and maintain JCI accreditation. Data suggests that patients benefit most from these large networks because they provide consistent access to hematopathology specialists who can accurately distinguish follicular lymphoma from more aggressive subtypes.
Patient Consensus: Many patients find that follicular lymphoma is managed like a chronic illness with repeated remissions. They emphasize that regular monitoring and access to standard drug regimens are more critical for long-term health than the specific treatment location.
Bone marrow transplants are recommended over immunotherapies when patients require first-line curative consolidation or have structural marrow failure. While immunotherapies treat relapsed cases, transplants offer superior durable survival for aggressive blood cancers. Specialists favor this approach when patients possess high physical fitness to withstand intensive conditioning.
Bookimed Expert Insight: India hosts massive specialized centers like Apollo Hospital Indraprastha and Global Hospital Chennai. These facilities manage over 1,000,000 patients annually and perform thousands of transplants. Our data shows that Indian hematologists like Dr. Girish Badarkhe often utilize transplants for patients showing rapid relapse. This high-volume expertise ensures better outcomes for complex follicular lymphoma cases compared to smaller regional clinics.
Patient Consensus: Patients note that transplant is a more aggressive option reserved for when the disease returns quickly. They emphasize it requires longer hospital stays and harder recovery than modern targeted immune treatments.
Indian oncologists recommend watch and wait for follicular lymphoma when the disease is asymptomatic or low-risk. This evidence-based strategy avoids unnecessary side effects and preservation of quality of life without reducing survival rates. It involves active monitoring with regular blood panels and imaging in JCI-accredited facilities.
Bookimed Expert Insight: Indian oncology centers like Medanta or HCG Manavata utilize precision diagnostics such as PET-CT and linear accelerators accurate to 1 mm. This high-resolution monitoring ensures that the exact moment of disease progression is captured. Our data shows many Indian specialists, including Dr. Girish Badarkhe, manage large patient volumes with 100,000+ global cases, offering extensive experience in timing these interventions correctly.
Patient Consensus: Patients emphasize that watch and wait is a proactive period involving frequent scans and exams. They often feel relieved to maintain their daily routines while avoiding the high costs of travel and intensive therapy until strictly necessary.